| Identification | Back Directory | [Name]
Estrogen receptor antagonist 2 | [CAS]
2222844-89-3 | [Synonyms]
AZD-9833
Estrogen receptor antagonist 2 | [Molecular Formula]
C24H28F4N6 | [MDL Number]
MFCD32708532 | [MOL File]
2222844-89-3.mol | [Molecular Weight]
476.51 |
| Chemical Properties | Back Directory | [Boiling point ]
590.2±50.0 °C(Predicted) | [density ]
1.318±0.06 g/cm3(Predicted) | [form ]
Solid | [pka]
14.25±0.60(Predicted) | [color ]
Off-white to light yellow | [InChIKey]
WDHOIABIERMLGY-CMJOXMDJSA-N | [SMILES]
C1=NC([C@@H]2C3=C(C4C=NNC=4C=C3)C[C@@H](C)N2CC(F)(F)F)=CC=C1NC1CN(CCCF)C1 |
| Hazard Information | Back Directory | [Uses]
Camizestrant (AZD-9833) is a potent and orally active estrogen receptor (ER) antagonist. Camizestrant is used for the study of ER+ HER2-advanced breast cancer[1]. | [in vivo]
Camizestrant (oral administration; 0.2-50 mg/kg; 20 days) exhibits anti-tumour efficacy as a dose-dependent manner in human parental MCF7 mice xenograft[1].
Camizestrant (oral administration; 0.8-40 mg/kg; 30 days) decreases tumor growth as a dose-dependent manner. It gives almost complete tumour growth inhibition at the doses >10 mg/kg in mice[1]. | Animal Model: | Human ESR1 mutant breast cancer patient derived xenograft with CTC174 cells in female NSG mice[1] | | Dosage: | 0.8 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 40 mg/kg | | Administration: | Oral administration; 30 days; once daily | | Result: | Inhibited tumor growth in a dose-dependent manner. |
| [References]
[1] Bernard Christophe Barlaam, etal. Chemical compounds. Patent US20180111931. |
|
| Company Name: |
ChemShuttle, Inc.
|
| Tel: |
0510-83588313-811 18800520310 |
| Website: |
https://www.jiehuapharma.com/ |
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
|